Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.64 |
| ▸ | F10 | P00742 | 5/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76558 | 0.84 | F10 (0.58) | PTGS2F10 | |
| SCHEMBL28834548 | 0.82 | F10 (0.54) | PTGS2F10AKR1C3 | |
| SCHEMBL28956907 | 0.82 | PTGS2 (0.67) | PTGS2F10 | |
| SCHEMBL19086541 | 0.82 | PTGS2 (0.64) | PTGS2F10 | |
| SCHEMBL15628319 | 0.82 | F10 (0.54) | PTGS2F10AKR1C3 | |
| SCHEMBL18630668 | 0.82 | F10 (0.54) | PTGS2F10AKR1C3 | |
| SCHEMBL2540317 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL92872 | 0.82 | PTGS2 (0.64) | PTGS2F10AKR1C3 | |
| SCHEMBL15846877 | 0.82 | F10 (0.54) | PTGS2F10 | |
| SCHEMBL198132 | 0.81 | PTGS2 (0.57) | PTGS2F10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | claimed |
| US-20260092054-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4596539-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | disclosed |
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024071439-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | 科研製薬株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3342765-B1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| CN-1675204-A | 2-heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092054-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | STAT6, HRH4, CCR6 | PTGS2 1010/4885F10 3331/4885AKR1C3 234/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | PTGS2 832/4885F10 4731/4885AKR1C3 4092/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | PTGS2 21/4885F10 1662/4885AKR1C3 682/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | PTGS2 21/4885F10 1662/4885AKR1C3 682/4885 |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | PTGS2 832/4885F10 4731/4885AKR1C3 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.